Incidence and risk factors of PICC-related thrombosis in breast cancer: a meta-analysis.

Abstract

The incidence and risk factors of peripherally inserted central catheter-related thrombosis in patients with breast cancer have not been fully elucidated. Meta-analysis was performed by searching all studies on the incidence of peripherally inserted central catheter-associated thrombosis and risk factors for its formation in breast cancer patients from the establishment of the database to May 2023, including PubMed, Embase, Web of Science, China Knowledge Network, China Biomedical Literature Service System (SinoMed) and Wanfang databases. Then the incidence of peripherally inserted central catheter-related thrombosis and risk factors for its formation were analyzed in breast cancer patients. A total of 15 articles were included, involving 8635 patients. The total incidence of peripherally inserted central catheter-related thrombosis in breast cancer patients was 7.0% (95% confidence interval: 4.0-13.0%) and 12.9% (95% confidence interval: 7.0-22.5%) after correction. Thirty-two risk factors were included, and eight risk factors could be combined. Among these risk factors, there were statistically significant differences (P<0.05) in body mass index≥25 (odds ratio=6.319, 95% confidence interval: 2.733-14.613; P<0.001), D-dimer >500ng/ml (odds ratio=1.436, 95% confidence interval: 1.113-1.854; P=0.005), increased fibrinogen (odds ratio=4.733, 95% confidence interval: 1.562-14.346; P=0.006), elevated platelet count (odds ratio=4.134, 95% confidence interval: 2.694-6.346; P<0.001) and catheter malposition (odds ratio=8.475, 95% confidence interval: 2.761-26.011; P<0.001). The incidence rate of peripherally inserted central catheter-related thrombosis in breast cancer patients was 7.0% (95% confidence interval: 4.0-13.0%). Body mass index≥25, D-dimer >500ng/ml, elevated fibrinogen, elevated platelet count and catheter malposition were risk factors for peripherally inserted central catheter-related thrombosis in breast cancer patients.